A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nadia Harbeck, MD, PhD
Head, Breast Center, Ludwig-Maximilians-University of Munich Department of Obstetrics and Gynecology Marchioninistr. 15, 81377 Munich, Germany
Principal Investigator - Nancy U. Lin, MD
Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
81 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Adelaide, Australia
- Research Site
Auchenflower, Australia
- Research Site
Clayton, Australia
- Research Site
Heidelberg, Australia
- Research Site
St Leonards, Australia
- Research Site
Subiaco, Australia
- Research Site
Anderlecht, Belgium
- Research Site
Bruges, Belgium
- Research Site
Leuven, Belgium
- Research Site
Liège, Belgium
- Research Site
Vancouver, British Columbia, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Copenhagen, Denmark
- Research Site
Herlev, Denmark
- Research Site
Odense C, Denmark
- Research Site
Helsinki, Finland
- Research Site
Tampere, Finland
- Research Site
Turku, Finland
- Research Site
Berlin, Germany
- Research Site
Dresden, Germany
- Research Site
Erlangen, Germany
- Research Site
Essen, Germany
- Research Site
Frankfurt, Germany
- Research Site
Hamburg, Germany
- Research Site
Hanover, Germany
- Research Site
Kiel, Germany
- Research Site
Mannheim, Germany
- Research Site
München, Germany
- Research Site
München, Germany
- Research Site
Münster, Germany
- Research Site
Tübingen, Germany
- Research Site
Cork, Ireland
- Research Site
Dublin, Ireland
- Research Site
Dublin, Ireland
- Research Site
Ancona, Italy
- Research Site
Bergamo, Italy
- Research Site
Catania, Italy
- Research Site
Milan, Italy
- Research Site
Naples, Italy
- Research Site
Padova, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Jun 2021
- Primary completion
- 8 Feb 2024
- Completion
- 26 May 2027
- Last update posted
- 12 May 2026
- Registered enrollment
- 506
- Registry id
- NCT04739761
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.